Prostate MRI: Not So Difficult. Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX

Similar documents
Current Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR

11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.

Prostate Cancer DFP Case of the Week

Prostate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)

Stephen McManus, MD David Levi, MD

PI-RADS V2 IN PRACTICE A PICTORIAL REVIEW

1 Uniform hyperintense signal intensity (normal). 2 Linear (arrow), wedge-shaped, or diffuse mild hypointensity, usually indistinct margin.

Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144

Multiparametric Prostate MRI: PI-RADS V.2

Essential Initial Activities and Clinical Outcomes

D. J. Margolis 1, S. Natarajan 2, D. Kumar 3, M. Macairan 4, R. Narayanan 3, and L. Marks 4

Utility of Prostate MRI. John R. Leyendecker, MD

Prostate MRI for local staging and surgical planning in prostate cancer

PROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging

Essentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis

Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template

Problems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence.

FieldStrength. Multi-parametric 3.0T MRI provides excellent prostate imaging

Prostate Cancer MRI. Accurate Diagnosis and Treatment. PSA to Prostate MRI. for patients and curious doctors

Prostate MRI: Who needs it?

Diffusion Weighted Imaging in Prostate Cancer

OASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER

Interac(ve Experience with Prostate Imaging Repor(ng and Data System Version 2 (PI-RADS v2)

Detection, Screening and. Jelle Barentsz, Radboudumc, Nijmegen, NL

Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer

PI-RADS classification: prognostic value for prostate cancer grading

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Optimizing Implementation of Prostate MRI. Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

MR-US Fusion Guided Biopsy: Is it fulfilling expectations?

Feasibility and initial dosimetric findings for a randomized trial using dose painted multi-parametric-mri defined targets in prostate cancer

Clinical Prostate Cancer Imaging

The role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination

Additional value of Diffusion Weighted Imaging in the detection and treatment of prostate cancer

MRI and Fusion biopsies. K Sahadevan Consultant Urologist

Anatomic Imaging of Prostate Cancer

Case Discussions: Prostate Cancer

Multiparametric MRI diagnostic value in a case of prostate cancer

da Vinci Prostatectomy

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Prostate Cancer 3/15/2017. CEUS of the Prostate. The Prostate Cancer Screening Dilemma Data. Incidence: 161,360 Deaths: 26,730

Prostate Cancer Imaging: most common pitfalls in multiparametric Magnetic Resonance

MR-TRUS Fusion Biopsy

Disclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None

Diagnosis and management of prostate cancer in the

PI-RADS version 2 - what we need to know

Prostate Biopsy in 2017

State-of-the-art: vision on the future. Urology

8/1/2017. PROSTATEx-2 Overview. Disclosures. Joint Imaging-Therapy Scientific Symposium: PROSTATEx-2 Challenge

MR Imaging of Prostate Cancer: Present Limitations and Future Directions

Essentials for establishing a successful MR-US fusion biopsy program

The Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation. Roberto Alonzi Mount Vernon Cancer Centre

Arterial Spin Labeling in Body MR

Standards for MRI reporting the evolution to PI-RADS v 2.0

MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review

prostate cancer diagnosis and patient management

How to detect and investigate Prostate Cancer before TRT

TRUS Guided Transrectal Prostate Biopsy

Emerging Techniques in Breast Imaging: Contrast-Enhanced Mammography and Fast MRI

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

Disclosures. Diffusion and Perfusion Imaging in the Head and Neck. Learning objectives ???

MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know

Prostate MRI: Access to and Current Practice of Prostate MRI in the United States

Imaging of prostate cancer local recurrences : why and how?

PCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."

Prostate Cancer. David Wilkinson MD Gulfshore Urology

HHS Public Access Author manuscript Abdom Radiol (NY). Author manuscript; available in PMC 2017 January 19.

Optimal Imaging and Technical Aspects of Prostate SRT

Supplemental Information

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER

Prostate Case Scenario 1

Adam Raben M.D. Helen F Graham Cancer Center

SEER Summary Stage Still Here!

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

Monitoring bony metastases response with diffusion MRI

Transformation of the South West Prostate Cancer Diagnostic Pathway. 14 th May 2018

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April

MRI Based treatment planning for with focus on prostate cancer. Xinglei Shen, MD Department of Radiation Oncology KUMC

Diagnosis, pathology and prognosis including variant pathology

Imaging: When to get MRI, CT or PET-CT?

Prostate MRI: Screening, Biopsy, Staging, and Ablation

Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.

Background. Nissar Sheikh 2 Cheng Wei 1 Magdalena Szewczyk Bieda 1,3 Annie Campbell 5 Shaukat Memon 2 Stephen Lang 4 Ghulam Nabi 1

AllinaHealthSystems 1

MEDICAL POLICY SUBJECT: MAGNETIC RESONANCE IMAGING PROSTATE/MULTIPARAMETRIC MRI EFFECTIVE DATE: 06/21/18

Prostate biopsy: MR imaging to the rescue

Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging

Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers

Low risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer

DTI fiber tracking at 3T MR using b-1000 value in the depiction of periprostatic nerve before and after nervesparing prostatectomy

Magnetic Resonance Imaging in the management of prostate cancer: What the Radiologists need to know?

Localized at a focus, central point or locus. Localized finding distinct from neighboring tissues, not a threedimensional

Automated Identification of Neoplasia in Diagnostic Imaging text reports

MR-US Fusion. Image-guided prostate biopsy. Richard E Fan Department of Urology Stanford University

The utility of transrectal sonoelastography in preoperative prostate cancer assessment

Hospital, University of Bologna, Bologna, Italy. Department of Urology, University of Bologna, Sant Orsola-Malpighi Hospital, Bologna, Italy

20 Prostate Cancer Dan Ash

Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality

COLORECTAL CANCER STAGING in 2010

Alexander S. Somwaru 1*, Deepu Alex 2 and Atif Zaheer 3

Transcription:

Prostate MRI: Not So Difficult Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX

What is the biggest barrier to your practice incorporating prostate MRI? 1) I don t know how to read the cases 2) I don t know how to report the cases 3) The endorectal coil 4) Limitations to data processing (DCE, DWI)

How many prostate MRI exams does your practice perform? 1) Zero 2) 2/week 3) 3-5/week 4) 6-10/week 5) > 10/week

Designate a Champion Know your subject Imaging Techniques Clinical Consider 1 wk training at program w/high volume Know the concerns of your referring MDs Urology Radiation Oncology Medical Oncology

The MRI Tool Kit Standard imaging Axial T1W T2W Coronal T2W Dynamic contrast enhanced imaging Axial Diffusion Axial Spectroscopy

Plan the Exam: 45 min slot start with a 1 hr slot Set-up (10 min) ERC insertion Glucagon injection Positioning Plan scan (inc sag T2) Standard imaging (15 min) T1 weighted (4 minutes) T2 weighted (11 minutes) Axial, Coronal Diffusion (5 min) b values 0, 800-1000; DCE imaging (10 min) T1 GRE Facilitated with post-processing

Focus On Key Issues PSA / bx mismatch for staging High PSA, low Gleason, low volume Low PSA, high Gleason, any volume Rising PSA, repeat negative bx Detect a focus for biopsy

Endorectal Coil MRI Advantages Higher spatial resolution for equivalent time Staging advantage Faster imaging, all other parameters constant Disadvantages Can be uncomfortable Requires experience for optimal placement Best with prep (enema) & glucagon Patient and MD pre-conceptions

Interpretation tips Detection PZ is rarely classic (stranding) Strongest evidence w/ multi-paramter + Low signal T2, w/o high signal T1 DCE: Rapid uptake & washout DWI: High signal on high B value, Low on ADC Staging Read with high specificity Better with ERC Better with 3T DWI ADC map

Size Matters Transverse/axial Sosna, et al. Acad Radiol. 2003 Aug; 10(8):846-53 Bulman, et al. Radiology. 2012 Jan;262(1):144-51. Sagittal

Report Find reporting structure for key referents Keep reporting structure consistent Get familiar with PIRADS

Report Technique (brief!) Overall gland morphology Report size & volume Use sagittal view: AP and CC Use axial view: transverse (Even better planimetry, but time consuming) Features of BPH Describe delineation of PZ

Report: Abnormal Foci Describe with degree of suspicion T2, DCE and DWI congruent? CONSISTENT WITH 2 of 3 Very suspicious 1 of 3 Some features suggestive of Depends on how compelling that 1 is

Report- The Suspicious Foci Describe Position Ax: Clock position, CC: gland into 1/3 s Radial: gland into 1/3 s Describe distance in touch with outer margin Distinguish < vs. > 1.2 cm Describe contour with reference to lesion(s) Describe neurovasc triangles Clearly seen Not well delineated Infiltrated by tumor.

Report: Outside the Gland Describe seminal vesicles Symmetry Visualization / atrophy Multi-parametric features Describe LN s using size criteria.. Describe Bones

76 y.o; PSA = 31; 3 prior neg bx rounds 2.5 x 1.6 cm REPORT: An anterior mass is seen with uniform low signal intensity on T2WI s, measuring 2.5 x 1.6cm, demonstrating abnormal contrast features, very suspicious for cancer. It is located at the mid- portion of gland (C-C dimension) from the 11:00 1:00 position (gland viewed from a lithotomy perspective). A biopsy targeted towards this area is expected to have a high positive yield. There is no definite evidence for extra-capsular extension. IMPRESSION: Anterior gland tumor as described above. Consider targeted biopsy.

Establish & Maintain Credibility Under-promise, over-deliver Follow-up on path Communicate Seek 2 nd opinions on difficult cases Stay current with the literature Ours and theirs!

Pt with progression on active surveillance T2WI Diffusion MAP Van As, et al. Eur Urol. 2009 Dec;56(6):981-7 ADC = 628 mm 2 /s. Tumor ADC was a significant predictor of: 1) adverse repeat biopsy findings (p<0.0001; hazard ratio [HR]: 1.3; 95% CI: 1.1-1.6), 2) time to radical treatment (p<0.0001; HR: 1.5; 95% CI: 1.2-1.8)

Conclusions Prostate MRI offers value to pts & MDs Requires a champion Use standard techniques Buy-in w/dialogue